Search

Displaying results 181 - 190 of 489 in total
  1. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  2. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).

  3. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.

  4. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.

  5. Drug

    Butobarbital

    go.drugbank.com/drugs/DB01353
    ApprovedIllicit

    Butobarbital is a sedative and a hypnotic drug.

  6. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.

  7. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with ...

  8. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may ...

  9. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.

  10. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800]